Literature DB >> 12875989

Pathology and pathogenesis of bioterrorism-related inhalational anthrax.

Jeannette Guarner1, John A Jernigan, Wun-Ju Shieh, Kathleen Tatti, Lisa M Flannagan, David S Stephens, Tanja Popovic, David A Ashford, Bradley A Perkins, Sherif R Zaki.   

Abstract

During October and November 2001, public health authorities investigated 11 patients with inhalational anthrax related to a bioterrorism attack in the United States. Formalin-fixed samples from 8 patients were available for pathological and immunohistochemical (IHC) study using monoclonal antibodies against the Bacillus anthracis cell wall and capsule. Prominent serosanguinous pleural effusions and hemorrhagic mediastinitis were found in 5 patients who died. Pulmonary infiltrates seen on chest radiographs corresponded to intraalveolar edema and hyaline membranes. IHC assays demonstrated abundant intra- and extracellular bacilli, bacillary fragments, and granular antigen-staining in mediastinal lymph nodes, surrounding soft tissues, and pleura. IHC staining in lung, liver, spleen, and intestine was present primarily inside blood vessels and sinusoids. Gram's staining of tissues was not consistently positive. In 3 surviving patients, IHC of pleural samples demonstrated abundant granular antigen-staining and rare bacilli while transbronchial biopsies showed granular antigen-staining in interstitial cells. In surviving patients, bacilli were not observed with gram's stains. Pathological and IHC studies of patients who died of bioterrorism-related inhalational anthrax confirmed the route of infection. IHC was indispensable for diagnosis of surviving anthrax cases. The presence of B. anthracis antigens in the pleurae could explain the prominent and persistent hemorrhagic pleural effusions.

Entities:  

Mesh:

Year:  2003        PMID: 12875989      PMCID: PMC1868222          DOI: 10.1016/S0002-9440(10)63697-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-11-09       Impact factor: 17.586

2.  Update: investigation of bioterrorism-related inhalational anthrax--Connecticut, 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-11-30       Impact factor: 17.586

3.  Pulmonary anthrax caused by contaminated sacks.

Authors:  J B Enticknap; N S Galbraith; A J Tomlinson; T F Elias-Jones
Journal:  Br J Ind Med       Date:  1968-01

4.  Death due to bioterrorism-related inhalational anthrax: report of 2 patients.

Authors:  L Borio; D Frank; V Mani; C Chiriboga; M Pollanen; M Ripple; S Ali; C DiAngelo; J Lee; J Arden; J Titus; D Fowler; T O'Toole; H Masur; J Bartlett; T Inglesby
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

5.  Immunohistochemical detection of Yersinia pestis in formalin-fixed, paraffin-embedded tissue.

Authors:  Jeannette Guarner; Wun-Ju Shieh; Patricia W Greer; Jean-Marc Gabastou; May Chu; Edward Hayes; Kurt B Nolte; Sherif R Zaki
Journal:  Am J Clin Pathol       Date:  2002-02       Impact factor: 2.493

6.  Fatal inhalational anthrax in a 94-year-old Connecticut woman.

Authors:  Lydia A Barakat; Howard L Quentzel; John A Jernigan; David L Kirschke; Kevin Griffith; Stephen M Spear; Katherine Kelley; Diane Barden; Donald Mayo; David S Stephens; Tanja Popovic; Chung Marston; Sherif R Zaki; Jeanette Guarner; Wun-Ju Shieh; H Wayne Carver; Richard F Meyer; David L Swerdlow; Eric E Mast; James L Hadler
Journal:  JAMA       Date:  2002-02-20       Impact factor: 56.272

7.  Fatal case of inhalational anthrax mimicking intra-abdominal sepsis.

Authors:  Richard Quintiliani; Richard Quintiliani
Journal:  Conn Med       Date:  2002-05

8.  A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis.

Authors:  Barun K De; Sandra L Bragg; Gary N Sanden; Kathy E Wilson; Lois A Diem; Chung K Marston; Alex R Hoffmaster; Gwen A Barnett; Robbin S Weyant; Teresa G Abshire; John W Ezzell; Tanja Popovic
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

9.  Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis.

Authors:  Alex R Hoffmaster; Richard F Meyer; Michael D Bowen; Chung K Marston; Robbin S Weyant; Kathy Thurman; Sharon L Messenger; Erin E Minor; Jonas M Winchell; Max V Rassmussen; Bruce R Newton; J Todd Parker; William E Morrill; Nancy McKinney; Gwen A Barnett; James J Sejvar; John A Jernigan; Bradley A Perkins; Tanja Popovic
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  73 in total

Review 1.  Exposing a killer: pathologists angle for anthrax.

Authors:  Stephen W Chensue
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  Key tissue targets responsible for anthrax-toxin-induced lethality.

Authors:  Shihui Liu; Yi Zhang; Mahtab Moayeri; Jie Liu; Devorah Crown; Rasem J Fattah; Alexander N Wein; Zu-Xi Yu; Toren Finkel; Stephen H Leppla
Journal:  Nature       Date:  2013-08-28       Impact factor: 49.962

3.  The superoxide dismutases of Bacillus anthracis do not cooperatively protect against endogenous superoxide stress.

Authors:  Karla D Passalacqua; Nicholas H Bergman; Amy Herring-Palmer; Philip Hanna
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

4.  Histopathology in a murine model of anthrax.

Authors:  Scott Duong; Lucius Chiaraviglio; James E Kirby
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

5.  Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.

Authors:  Der-Shan Sun; Po-Chien Lee; Jyh-Hwa Kau; Yung-Luen Shih; Hsin-Hsien Huang; Chen-Ru Li; Chin-Cheng Lee; Yu-Ping Wu; Kuo-Ching Chen; Hsin-Hou Chang
Journal:  Virulence       Date:  2015-04-23       Impact factor: 5.882

6.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Transcriptional profiling of Bacillus anthracis during infection of host macrophages.

Authors:  Nicholas H Bergman; Erica C Anderson; Ellen E Swenson; Brian K Janes; Nathan Fisher; Matthew M Niemeyer; Amy D Miyoshi; Philip C Hanna
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

8.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.

Authors:  Xia Zhang; Elizabeth Ambrose Amin
Journal:  J Mol Graph Model       Date:  2015-11-17       Impact factor: 2.518

10.  Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.

Authors:  Jennifer L Bromberg-White; Elissa Boguslawski; Nicholas S Duesbery
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.